Austedo XR: FDA Approved for tardive Dyskinesia
In a significant advancement for those suffering from tardive dyskinesia (TD), the U.S. Food and Drug Administration (FDA) recently approved Austedo XR (extended-release deutetrabenazine). This approval brings a new, convenient treatment option for patients grappling with this often debilitating condition.
The most notable advantage of Austedo XR is its once-daily dosing regimen. This is a significant improvement over the immediate-release form, which requires twice-daily dosing. A once-daily pill is easier for patients to adhere to, improving overall treatment compliance.
WATCH YOUTUBE VIDEO FOR DETAILS:
FOR ACADEMY MEMBERS:
Comparing VMAT-2 Inhibitors for Tardive Dyskinesia: [Join us Live]
Join our Live video session on June 2 AT 4 PM PST.
In this session. Dr. Harvinder Singh will compare VMAT-2 inhibitors (Tetrabenazine, Deutetrabenazine and Valbenazine) in the following sections:
- Dosing & Strengths: Which one is most and least favorable in terms of dosing, titration and amount of pills needed per day?
- How to Dose & Titrate each VMAT-2 inhibitor?
- Comparing use of each medication in special population.
- Comparing Contraindications.
- Understanding the role of genotyping: Drug interactions & CYP450.
- Comparing common side effects.
Here is one slide from this presentation on
“How to Dose each VMAT-2 Inhibitor for TD management“
Comparing VMAT-2 Inhibitors for Tardive Dyskinesia
INTERESTED IN ACCESS TO THIS & OTHER CLINICALLY RELEVANT LECTURE SERIES?
JOIN ACADEMY MEMBERSHIP:
This is a closed membership for medical professionals only.
- 400+ Clinically Relevant Chapters: Each chapter within these sections is of direct clinical relevance for your daily practice. (Table of Content)
- Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice. (Read Content)
- Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine. (Read Content)
- Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases. (Academy Network)
- Goal: is to have all important clinically relevant topics in one place for ease of access.
DISCOUNTS AVAILABLE FOR: Residents & Students ONLY.
Email us your student information (program information and way to confirm your student status) to: HSingh@PsychiatryEducationForum.com
© 2024 All Rights Reserved.
